The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer.
Aromatase inhibitors (AIs) have become the standard adjuvant therapy of postmenopausal breast cancer survivors. AIs induce a reduction of bioavailable estrogens by inhibiting aromatase, which would be expected to induce alterations in body composition, more extensive than induced by menopause. The objectives are to examine the impact of AIs on (1) DXA-scan derived body composition and (2) gonadal hormone levels. This is a sub-analysis of a 2-year double-blind, placebo-controlled, randomized trial of 82 women with nonmetastatic breast cancer, newly menopausal following chemotherapy, who were randomized to risedronate (35 mg once weekly) versus placebo, and stratified for their usage of AI versus no AI. Outcomes included DXA-scan derived body composition and gonadal hormone levels. As a group, total body mass increased in women over 24 months. Women on AIs gained a significant amount of lean body mass compared to baseline as well as to no-AI users (P < 0.05). Women not on an AI gained total body fat compared to baseline and AI users (P < 0.05). Free testosterone significantly increased and sex hormone binding globulin (SHBG) significantly decreased in women on AIs compared to no AIs at 24 months (P < 0.01) while total estradiol and testosterone levels remained stable. Independent of AI usage, chemotherapy-induced postmenopausal breast cancer patients demonstrated an increase of total body mass. AI users demonstrated maintenance of total body fat, an increase in lean body mass and free testosterone levels, and a decrease in SHBG levels compared to no-AI users. The mechanisms and implications of these changes need to be studied further.
Medicine, University of Pittsburgh, Kaufmann Medical Bldg, Pittsburgh, PA, 15213, USA. vanLondenJ@upmc.edu
G J
GJ
van Londen
S
S
Perera
K
K
Vujevich
P
P
Rastogi
B
B
Lembersky
A
A
Brufsky
V
V
Vogel
S L
SL
Greenspan
D000273:Adipose Tissue / Q000502:physiology; D047072:Aromatase Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D001823:Body Composition / Q000187:drug effects*; D015992:Body Mass Index; D015519:Bone Density / Q000187:drug effects*; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology; D004311:Double-Blind Method; D012968:Etidronic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D042341:Gonadal Hormones / Q000097:blood*; D006801:Humans; D008875:Middle Aged; D010919:Placebos; D017698:Postmenopause; D000068296:Risedronic Acid; D012738:Sex Hormone-Binding Globulin / Q000032:analysis
D047072:Aromatase Inhibitors; D042341:Gonadal Hormones; D010919:Placebos; D012738:Sex Hormone-Binding Globulin; D000068296:Risedronic Acid; D012968:Etidronic Acid